Literature DB >> 1991808

The course of biochemical parameters of bone turnover during treatment with corticosteroids.

M F Prummel1, W M Wiersinga, P Lips, G T Sanders, H P Sauerwein.   

Abstract

The mechanisms by which glucocorticoids cause osteopenia are incompletely understood. It is generally accepted that bone formation is depressed during corticosteroid treatment, but the cause of the ongoing bone resorption is less clear. Secondary hyperparathyroidism and changes in vitamin D metabolism are thought to play a role. This is based mostly on data from cross-sectional studies in heterogeneous patient groups. We, therefore, studied longitudinally the course of biochemical parameters and the hormones influencing bone turnover in a homogeneous group of 10 euthyroid patients with Graves' ophthalmopathy, all euthyroid for at least 1 yr before, during, and after a 12-week course of prednisone. Bone formation was depressed as reflected by a fall in serum osteocalcin (3.0 +/- 2.1, 1.7 +/- 1.1, and 2.4 +/- 1.9 micrograms/L at weeks 0, 4, and 12, respectively; P = 0.02) and in total alkaline phosphatase (1.15 +/- 0.33, 0.83 +/- 0.22, and 0.88 +/- 0.40 mukat/L; P = 0.001). Parameters of bone resorption (urinary hydroxyproline/creatinine ratio, serum acid phosphatase) and the levels of vitamin D metabolites remained unchanged. Serum intact PTH seemed to decrease slightly. Our findings suggest that glucocorticoid induced osteopenia is caused by a depressed bone formation in the presence of an unaltered but ongoing bone resorption. Secondary hyperparathyroidism and changes in vitamin D metabolism are apparently not involved.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991808     DOI: 10.1210/jcem-72-2-382

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

Review 1.  Glucocorticoid-induced osteoporosis.

Authors:  R S Weinstein
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

Authors:  Steven L Teitelbaum; Margaret P Seton; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2011-02

3.  Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Authors:  Jeffrey G Stark; Sybille Werner; Susanne Homrighausen; Yufei Tang; Michael Krieg; Hartmut Derendorf; Helmut Moellmann; Guenther Hochhaus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-22       Impact factor: 2.745

4.  Beclomethasone inhalation decreases serum osteocalcin concentrations.

Authors:  E M Pouw; M F Prummel; H Oosting; C M Roos; E Endert
Journal:  BMJ       Date:  1991-03-16

5.  Effects of continuous glucocorticoid infusion on bone metabolism in the rat.

Authors:  C S King; E C Weir; C W Gundberg; J Fox; K L Insogna
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

Review 6.  Endogenous Glucocorticoids and Bone.

Authors:  Hong Zhou; Mark S Cooper; Markus J Seibel
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 7.  Bone involvement in exogenous hypercortisolism.

Authors:  L Sinigaglia; D Mazzocchi; M Varenna
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

8.  Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism.

Authors:  Tara C Brennan-Speranza; Holger Henneicke; Sylvia J Gasparini; Katharina I Blankenstein; Uta Heinevetter; Victoria C Cogger; Dmitri Svistounov; Yaqing Zhang; Gregory J Cooney; Frank Buttgereit; Colin R Dunstan; Caren Gundberg; Hong Zhou; Markus J Seibel
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

9.  Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis.

Authors:  R Rizzoli; T Chevalley; D O Slosman; J P Bonjour
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

10.  Quantification of bone mineral density to define osteoporosis in rat.

Authors:  M Srivastava; S K Mandal; S Sengupta; M Arshad; M M Singh
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.